Want to see INSM full AI Analyst Report?
INSM Stock Chart & Stats
$123.89
-$0.89(-0.83%)
At close: 4:00 PM EDT
$123.89
-$0.89(-0.83%)
Day’s Range― - ―
52-Week Range$90.39 - $212.75
Previous CloseN/A
Volume417.93K
Average Volume (3M)2.70M
Market Cap
$26.54B
Enterprise Value$22.76K
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$579.88M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 22, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding218,381,500
10 Day Avg. Volume1,676,967
30 Day Avg. Volume2,696,397
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$201.22Price Target Upside62.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$1.80B
Bulls Say, Bears Say
Bulls Say
BRINSUPRI Launch And Revenue GrowthRapid patient starts, expanding prescriber adoption and higher guidance indicate strong product-market fit. Sustained launch execution could establish BRINSUPRI as a major recurring revenue base and diversify growth beyond ARIKAYCE.
International Market ExpansionJapan approval expands the addressable commercial market and gives Insmed an additional regulated pathway for launching Brinsupri. It strengthens global positioning in a chronic, underserved respiratory disease while supporting longer-term revenue diversification.
TPIP Clinical DifferentiationDurable efficacy and tolerability data support TPIP’s potential as a differentiated once-daily prostanoid therapy. Progression toward Phase 3 across multiple indications could create a substantial future growth engine in high-need pulmonary markets.
Bears Say
Heavy Cash Burn And Ongoing LossesInsmed remains dependent on its cash balance while funding launches and clinical programs. Persistent operating losses and heavy free-cash-flow consumption could constrain flexibility if commercialization or clinical milestones take longer than expected.
Rising Investment And Milestone ObligationsHigher spending is necessary to support launches and Phase 3 development, but it delays breakeven and increases execution risk. The added milestone obligation creates further cash outflows before management’s targeted cash-flow positivity in 2027.
Reimbursement And Net-revenue PressureConstrained European reimbursement limits international upside, while rising gross-to-net deductions can reduce realized revenue as products mature. These pressures may weaken margins and make headline patient and sales growth less profitable.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $90.39 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $26.54B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Oct 22, 2026 which is in 49 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on Aug 06, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.672 by $0.612.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.39.
How many shares outstanding does Insmed have?
Insmed has 218,381,500 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.672. Following the earnings report the stock price went up 33.862%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$201.22 (62.42% Upside)
$201.22 (62.42% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $34.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
INSM Company Deck
INSM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and materially improved financial and clinical momentum — highlighted by BRINSUPRI’s historic launch ($309.2M Q2, raised FY guidance to $1.25B–$1.4B, peak >$7B), solid ARIKAYCE performance ($116.3M, +8% YoY) and compelling TPIP clinical data with upgraded peak potential (> $6B). Management emphasized a healthy cash position (~$1.2B) and a clear path to cash-flow positivity in 2027. Offsetting risks include higher near-term operating spend (R&D and SG&A +38% YoY), European reimbursement headwinds, milestone payments (~$50M H2 2026), and reliance on optimistic assumptions (diagnosis expansion, regulatory success, pricing). Overall, the positive commercial results, clinical readouts and funding runway substantially outweigh the noted operational and market uncertainties.View all INSM earnings summariesINSM Stock 12 Month Forecast
Average Price Target
$201.22
▲(62.42% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
United Therapeutics
―
Ultragenyx Pharmaceutical
―
Avalyn Pharma Inc
―
Ownership Overview
0.71% Insiders
31.41% Mutual Funds
36.27% Other Institutional Investors
14.78% Public Companies and Individual Investors